VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis
Authors
Nicholson, S.Tovey, H.
Elliott, Tony
Burnett, S. M.
Cruickshank, C.
Bahl, A.
Kirkbride, P.
Mitra, A. V.
Thomson, A. H.
Vasudev, N.
Venugopal, B.
Slade, R.
Tregellas, L.
Morgan, B.
Hassall, A.
Hall, E.
Pickering, L. M.
Affiliation
Mid & South Essex NHS Foundation Trust, Essex, UKIssue Date
2021
Metadata
Show full item recordAbstract
Background: We investigated the first-line activity of vinflunine in patients with penis cancer. Cisplatin-based combinations are commonly used, but survival is not prolonged; many patients are unfit for such treatment or experience toxicity that outweighs clinical benefit. Methods: Twenty-five patients with inoperable squamous carcinoma of the penis were recruited to a single-arm, Fleming-A'Hern exact phase II trial. Treatment comprised 4 cycles of vinflunine 320 mg/m2, given every 21 days. Primary endpoint was clinical benefit rate (CBR: objective responses plus stable disease) assessed after 4 cycles. Seven or more objective responses or disease stabilisations observed in 22 evaluable participants would exclude a CBR of <15%, with a true CBR of >40% being probable. Results: Twenty-two participants were evaluable. Ten objective responses or disease stabilisations were confirmed. CBR was 45.5%, meeting the primary endpoint; partial response rate was 27.3%. Seven patients received >4 cycles of vinflunine. Dose reduction or treatment delay was required for 20% of cycles. In all, 68% of patients experienced at least one grade 3 adverse event. Two deaths on treatment were not caused by disease progression. Conclusions: Pre-specified clinical activity threshold was exceeded. Toxicity was in keeping with experience in other tumours. Vinflunine merits further study in this disease.Citation
Nicholson S, Tovey H, Elliott T, Burnett SM, Cruickshank C, Bahl A, et al. VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis [Internet]. British Journal of Cancer. Springer Science and Business Media LLC; 2021.Journal
British Journal of CancerDOI
10.1038/s41416-021-01574-9PubMed ID
34671131Additional Links
https://dx.doi.org/10.1038/s41416-021-01574-9Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41416-021-01574-9
Scopus Count
Collections
Related articles
- Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).
- Authors: Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, Elliott T, Thomson A, Burnett S, Cruickshank C, Carrington B, Waters R, Bahl A
- Issue date: 2013 Nov 12
- Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
- Authors: Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C
- Issue date: 2018 Aug
- Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.
- Authors: Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, D'Aniello C, Puglia L, Petremolo A, Ferro M, Marinelli A, Palmieri G, Sonpavde G, Mirone V, De Placido S
- Issue date: 2012 Dec
- Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
- Authors: Shah CH, Pappot H, Agerbæk M, Holmsten K, Jäderling F, Yachnin J, Grybäck P, von der Maase H, Ullén A
- Issue date: 2019 Jun
- Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
- Authors: Schöffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR
- Issue date: 1999 Jan